参考文献/References:
[1] Shattil SJ,Newman PJ.Integrins: dynamic scaffolds for adhesion and signaling in platelets[J].Blood,2004,104(6):1606-1615.
[2]Schwarz M,Meade G,Stoll P,et al.Conformation-specific blockade of the integrin gpiib/iiia: a novel antiplatelet strategy that selectively targets activated plate- lets[J].Circ Res,2006,99(1):25-33.
[3]Van't Hof AW,Ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME 2):a multicentre, double-blind, randomised controlled trial[J].Lancet,2008,372(9638):537-546.
[4]Valgimigli M,Biondi-Zoccai G,Tebaldi M,et al.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials[J].Eur Heart,2010,31(1):35-49.
[5]Ishikawa T,Shimizu M,Kohara S,et al.Appearance of wbc-platelet complex in acute ischemic stroke, predominantly in atherothrombotic infarction[J].J Atheroscler Thromb,2012,19(5):494-501.
[6]Coller BS.Anti-gpⅡb/Ⅲa drugs: current strategies and future directions[J].Thromb Haemost,2001,86(1):427-443.
[7]Yi HJ,Gupta R,Jovin TG,et al.Initial experience with the use of intravenous eptifibatide bolus during endovascular treatment of intracranial aneurysms[J].AJNR Am J Neuroradiol,2006,27(9):1856-1860.
[8]秦华,梁先明.新型血小板GPⅡb /Ⅲa 受体拮抗剂盐酸替罗非班[J].中国新药杂志,2002,11(3):197-200.
[9]McClellan KJ,Goa KL.Tirofiban. A review of its use in acute coronary syndromes[J]. Drugs,1998,56(6):1067-1080.
[10]Xu TY,Zhao H,Qiao ZQ,et al.Combined use of external therapeutic ultrasound and tirofiban has synergistic therapeutic effects on no-reflow after myocardial reperfusion[J].Echocardiography,2018,35(10):1671-1679.
[11]Chang ST,YangYT,Chu CM,et al.The Protein kinases are involved in the cardioprotective effects activated by platelet glycoprotein Ⅱb/Ⅲa inhibitor tirofiban at reperfusion in rats in vivo[J].Eur J Pharmacol,2018,8(5):33-38.
[12]Feng L,Liu J,Liu Y,et al.Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion[J].Exp Ther Med,2016,11(3):1011-1016.
[13]BedersonJB,PittsLH,TsujiM,et al.Rat middle cerebral artery occlusion: evaluation of themodelanddevelopmentofaneurologicexamination[J].Stroke,1986,17(3):472-476.
[14]Lincoff AM,Popma JJ,Ellis SG,et al.Abrupt vessel closure complicating coronary angioplasty: clini- cal, angiographic and therapeutic profile[J].J Am Coll Cardiol,1992,19(5):926-935.
[15]FabrisE,OttervangerJP,HermanidesRS,et al.Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention[J].Catheter Cardiovasc Interv,2019,93(5):293-297.
[16]AndersonGL,OsbornJL,NeiSD,et al.Comparison of in-hospital bleeding and cardiovascular events with high-dose bolus tirofiban and shortened infusion to short-duration eptifibatide as adjunctive therapy for percutaneous coronary intervention[J].Am J Cardiol,2019,123(1):44-49.
[17]VelibeyY,GuvencTS,DemirK,OzA,et al.Effects of bailout tirofiban on in-hospital outcomes and long-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention[J].2019,70(5):431-439.
[18]Jeong HG,Kim BJ,Yang MH,et al.Neuroimag- ing markers for early neurologic deteriorationin single small subcortical infarction[J].Stroke,2015,46(3):687-691.
[19]Kim SK,Song P,Hong JM,et al.Prediction of progressive motor deficits in patients with deep subcortical infarction. Cerebrovasc Dis[J].Cerebrovasc Dis,2008,25(4):297-303.
[20]Torgano G,Zecca B,Monzani V,et al.Effect of intravenous tirofiban and aspirinin reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial[J].Cerebrovasc Dis,2010,29(3):275-2781.
[21]LinL,LiW,LiuCC,et al.Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies[J].J Neurol Sci,2017,15(5):175-179.
[22]Philipps J,Thomalla G,Glahn J,et al.Treat- ment of progressive stroke with tirofiban-experience in 35patients[J].Cerebrovasc Dis,2009,2(5):435-438.
[23]Siebler M,Hennerici MG,Schneider D,et al.Safety of tirofiban in acute ischemic stroke: the satis trial[J].Stroke,2011,42(9):2388-2392.
[24]LiW,WuY,LiXS,et al.Intravenous tirofiban therapy for patients with capsular warning syndrome[J].StrokeVasc Neurol,2019,4(1):36-42.
[25]刘志强,彭小英.两种抗血小板方案治疗反复TIA的疗效比较研究[J].中国现代医生,2017,55(36):113-115.
[26] Wu RC,Chou PT,Chen LK.Aspirin plus tirofiban inhibit the thrombosis induced by Russell's viper venom[J].Thromb J,2016,14(1):38.
[27] HaertenK,KrabbeC,RaiberM.Efficacy and safety of treatment of acute ischemic stroke with glycoprotein Ⅱb/Ⅲa receptor blocker in routine clinical practice[J].DtschMedWochenschr,2004,129(12):67-71.
[28] 张光妍,高俊杰,陈文荣,等.小剂量替罗非班联合双抗血小板治疗进展性脑梗死的效果观察[J].广东医科大学学报,2018,36(3),285-287.
[29] 王升,刘梦,郑远征,等.小剂量替罗非班与双抗治疗进展性脑卒中的疗效对比及安全性评价[J].中国实用神经疾病杂志,2018,20(8):23-25.
[30] Rha JH,Saver JL.The impact of recanalization on ischemicstroke outcome: a meta-analysis[J].Stroke,2007,38(3):967-973.
[31] Rubiera M,Alvarez-Sabin J,Ribo M,et al.Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization inacute ischemic stroke[J].Stroke,2005,36(7):1452-1456.
[32] Junghans U,Seitz RJ,Wittsack HJ,et al.Treatment of acute basilar artery thrombosis with a combina- tion of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein iib/iiia inhibitor: report of four cases[J].Radiology,2001,221(3):795-801.
[33] Seitz RJ, Sukiennik J,Siebler M.Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban[J].Neurol Int,2012,4(2):e9.
[34] Teng D,Pannell JS,Rennert RC,et al.Endothelial trauma from mechanical thrombectomy in acute stroke:invitrolive-cellplatformwithanimalvalidation[J].Stroke,2015,46(4):1099-1106.
[35] Power S,Matouk C,Casaubon LK,et al.Vessel wall magnetic resonance imaging in acute ischemic stroke: effects of embolism and mechanical thrombec- tomy on the arterial wall[J].Stroke,2014,45(8):2330-2334.
[36] LuoY,YangY,XieY,et al.Therapeutic effect of pre-operative tirofiban on patients with acute ischemic stroke with mechanical thrombectomy within 6-24 hours[J].Interv Neuroradiol,2019,21(6):1374-1380.
[37] PanX,ZhengD,ZhengY,ChanPWL,et al.Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke[J].Eur J Neurol,2019,21(6):253-258.
[38] YuT,LinY,JinA,et al.Safety and efficiency of low dose intra-arterial tirofiban in mechanical thrombectomy during acute ischemic stroke[J].Curr Neurovasc Res,2018,15(2):145-150.
[39] ZhaoW,CheR,ShangS,et al.Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy[J].Stroke,2017,48(12):145-150.
[40] Ernst M,Butscheid F,Fiehler J,et al.Glycoprotein iib/iiia inhibitor bridging and subsequent endovasculartherapyinvertebrobasilarocclusionin120patients.Clin Neuroradiol,2016,26(2):169-175.
[41] ZhangS,HaoY,TianX,et al.Safety of intra-arterial tirofiban administration in ischemic stroke patients after unsuccessful mechanical thrombectomy[J].J Vasc Interv Radiol,2019,30(2):258-263.
[42] WuY,YinC,YangJ,et al.Endovascular thrombectomy[J].stroke,2018,49(11):2783-2785.
[43] LeeJI,GliemM,GerdesG,et al.Safety of bridging antiplatelet therapy with the gpⅡb-Ⅲa inhibitor tirofiban after emergency stenting in stroke[J].PLoS ONE,2017,12(12):362-367.
[44] AlexanderKP,ChenAY,NewbyLK,et al.Sex differences in major bleeding with gly- coprotein iib/iiia inhibitors: results from the crusade(can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementationof the acc/aha guidelines)initiative[J].Circulation,2006,114(13):1380-1387.
[45] 替罗非班在冠状动脉粥样硬化性心脏病治疗的中国专家共识[J].中华内科杂志,2013,52(5):434-439.
[46] 徐桂中,刘显灼,艾芬.冠状动脉介入术后并发严重血小板减少1例[J].临床心血管病杂志,2014,30(5):459-460.
[47] Nettersheim FS,Hohmann C,Pfister R,et al.Severe tirofiban-induced thrombocytopenia and thrombotic microangiopathy after percutaneous coronary intervention[J].Dtsch Med Wochenschr,2019,144(2):456-459.
[48] YiYH,YinWJ,GuZC,et al.A simple clinical pre-procedure risk model for predicting thrombocytopenia associated with periprocedural use of tirofiban in patients undergoing percutaneous coronary intervention[J].Front Pharmacol,2018,9(7):1667-1676.
[49] AdamoM,AriottiS,CostaF,et al.Phosphateor citrate-buffered tirofiban versus unfractionated heparin and its impact on thrombocytopenia and clinical outcomes in patients with acute coronary syndrome: A post hoc analysis from the PRISM trial[J].JACC Cardiovasc Interv,2016,9(16):276-281.
[50] Zhou X,Peng H,Yin Y,et al.Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia[J].Int J Cardiol,2016,206:93-94.
[51] Elcioglu OC,Ozkok A,Akpnar TS,et al.Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review[J].Int J Hematol,2012,96(3):370-375.
[52] AlexanderKP,ChenAY,NewbyLK,et al.Sex differences in major bleeding with gly- coprotein iib/iiia inhibitors: results from the crusade(can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the acc/aha guidelines)initiative[J].Circulation,2006,114(13):1380-1387.